Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors TMPRSS2-ERG gene fusions are frequently found in ...
Bottom Line: Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify ...
Testing for the genetic anomaly TMPRSS2:ERG in conjunction with use prostate cancer antigen 3 (PCA3) is better at predicting the presence of prostate cancer (PCa) than either marker alone, according ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results